Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Takashi Kawahara, Hiroki Ide, Eiji Kashiwagi, John Patterson, Satoshi Inoue, Hasanain Khaleel Shareef, Ali Kadhim Aljarah, Yichun Zheng, Alexander S. Baras, Hiroshi MiyamotoPubMed 2015

TL;DR

This study reveals that silodosin, a drug commonly used for benign prostatic hyperplasia, can inhibit bladder cancer cell growth and migration by inactivating the ELK1 transcription factor. Crucially, silodosin also sensitizes these cancer cells to cisplatin chemotherapy, offering a potential new strategy to overcome treatment resistance in patients with ELK1-positive urothelial carcinoma.

What Problem Does This Paper Address?

Muscle-invasive bladder cancer is a significant clinical challenge, and while cisplatin-based chemotherapy is a primary treatment, many patients develop intrinsic or acquired resistance. This resistance is a major hurdle, limiting treatment efficacy and leading to poorer outcomes. The paper aims to identify molecular targets and therapeutic strategies to overcome this chemoresistance. Specifically, it builds upon previous findings linking the ELK1 transcription factor to cancer progression and drug resistance, and investigates whether silodosin, known to affect ELK1 in other tissues, can be leveraged to combat bladder cancer and its resistance to chemotherapy.

Methods

The researchers employed a multi-pronged approach using various bladder cancer cell lines and patient-derived tissue samples:

  • Quantitative RT-PCR and Western Blotting: These standard molecular biology techniques were used to measure the expression levels of ELK1, c-fos, α1A-AR, and NF-κB at both the mRNA and protein levels. This allowed them to assess how silodosin treatment affected the abundance of these key molecules.
  • Luciferase Reporter Assays: To evaluate the transcriptional activity of ELK1 and NF-κB, reporter gene assays were utilized. Cells were transfected with plasmids containing luciferase genes under the control of ELK1 or NF-κB responsive elements. Silodosin's effect on luciferase activity provided a direct measure of its impact on the activity of these transcription factors.
  • Cell Viability Assays (MTT): The MTT assay was used to quantify cell proliferation and viability. This was crucial for assessing the direct effects of silodosin on cancer cell growth and its ability to enhance the cytotoxic effects of chemotherapy drugs like cisplatin and gemcitabine.
  • Cell Migration Assays (Scratch Wound Healing): This assay was employed to measure the ability of cancer cells to migrate, a process often linked to tumor invasion and metastasis.
  • RNA Interference (shRNA): To specifically investigate the role of ELK1, cells were engineered to stably express short hairpin RNA (shRNA) targeting ELK1, effectively "knocking down" its expression. This allowed for a direct comparison of silodosin's effects in the presence and absence of functional ELK1.
  • Immunohistochemistry: This technique was used to visualize the expression of phosphorylated ELK1 (p-ELK1) in human bladder cancer tissue microarrays (TMAs) from patients who received neoadjuvant chemotherapy. This allowed for a correlation between p-ELK1 levels and treatment response.

Datasets

The study utilized established human urothelial carcinoma cell lines: TCCSUP, UMUC3, 647V, and 5637. Additionally, UMUC3 cell lines stably expressing ELK1-shRNA or control shRNA were generated. Patient-derived bladder tissue microarrays (TMAs) from individuals who received neoadjuvant chemotherapy were also used for immunohistochemical analysis. No new benchmarks were introduced.

Key Insights and Ideas

  • Silodosin as an ELK1 Inhibitor in Bladder Cancer: The study provides strong evidence that silodosin, beyond its known effects in prostate tissue, effectively inactivates ELK1 in bladder cancer cells. This is a significant finding as it suggests a repurposing potential for silodosin in oncology.
  • ELK1 as a Driver of Bladder Cancer Proliferation and Migration: The research reinforces the role of ELK1 in promoting bladder cancer cell growth and migration, particularly in androgen receptor (AR)-positive cells, but also in an AR-independent manner for migration.
  • ELK1 Positivity as a Predictor of Chemoresistance: The correlation between high p-ELK1 expression in patient tumors and resistance to neoadjuvant chemotherapy is a critical clinical insight. This suggests that p-ELK1 could serve as a biomarker to identify patients who might benefit from alternative or combination therapies.
  • Synergistic Effect with Cisplatin: The most impactful finding is that silodosin significantly enhances the cytotoxic activity of cisplatin. This suggests a powerful combination therapy approach that could overcome resistance mechanisms.
  • NF-κB Modulation: Silodosin's ability to decrease NF-κB expression and activity, a known regulator of chemoresistance, provides a potential molecular mechanism for its chemosensitizing effects.

Key Results

  • Silodosin significantly reduced ELK1 mRNA and protein expression, as well as its transcriptional activity, in bladder cancer cell lines.
  • Silodosin inhibited the viability of androgen receptor (AR)-positive/ELK1-positive bladder cancer cells in the presence of androgens and also inhibited cell migration.
  • Silodosin treatment or ELK1 silencing significantly increased the sensitivity of bladder cancer cells to cisplatin, but not gemcitabine.
  • Silodosin decreased the expression and transcriptional activity of NF-κB.
  • In patient samples, high p-ELK1 positivity in bladder cancer tumors strongly correlated with resistance to neoadjuvant chemotherapy.

Limitations and Future Work

The authors acknowledge that further studies are required to fully elucidate the therapeutic effects of silodosin, particularly in animal models for bladder cancer. They also highlight the need to understand the molecular mechanisms behind the differential effects of ELK1 and silodosin on cell proliferation versus migration/invasion, and on the cytotoxicities of CDDP versus GEM. The study focused on specific cell lines and patient cohorts, and future work could explore these findings in a broader range of bladder cancer subtypes and patient populations. The clinical translation of these findings, including determining optimal dosing and combination strategies, will be crucial.

Summary updated

Abstract

Silodosin, a selective α1A-adrenergic blocker prescribed for the symptomatic treatment of benign prostatic hyperplasia, was previously shown to decrease the expression of ELK1, a c-fos proto-oncogene regulator and a well-described downstream target of the PKC/Raf-1/ERK pathway, in human prostate smooth muscle cells. PKC/Raf-1/ERK activation has also been implicated in drug resistance. In the current study, we assessed the effects of silodosin on ELK1 expression/activity in bladder cancer cells as well as on their proliferation in the presence or absence of chemotherapeutic drugs, including cisplatin and gemcitabine. In bladder cancer cell lines, silodosin reduced the expression of ELK1 (mRNA/protein) and its downstream target, c-fos gene, as well as the transcriptional activity of ELK1. While silodosin alone (up to 10 μM) insignificantly affected the growth of bladder cancer cells cultured in androgen depleted conditions or those expressing ELK1-short hairpin RNA, it considerably inhibited the viability of androgen receptor (AR)-positive/ELK1-positive cells in the presence of androgens. Silodosin also inhibited the migration of ELK1-positive cells with or without a functional AR, but not that of ELK1 knockdown cells. Interestingly, silodosin treatment or ELK1 silencing resulted in increases in drug sensitivity to cisplatin, but not to gemcitabine, even in AR-negative cells or AR-positive cells cultured in an androgen-depleted condition. In addition, silodosin decreased the expression of NF-κB, a key regulator of chemoresistance, and its transcriptional activity. Moreover, immunohistochemistry in bladder cancer specimens from patients who received neoadjuvant chemotherapy revealed that phospho-ELK1 positivity strongly correlated with chemoresistance. Silodosin was thus found to not only inhibit cell viability and migration but also enhance the cytotoxic activity of cisplatin in bladder cancer lines via inactivating ELK1. Our results suggest that combined treatment with silodosin is useful for overcoming chemoresistance in patients with ELK1-positive urothelial carcinoma receiving cisplatin.
BibTeX
@inproceedings{kawahara2015silodosin,
  author = {Takashi Kawahara and Hiroki Ide and Eiji Kashiwagi and John Patterson and Satoshi Inoue and Hasanain Khaleel Shareef and Ali Kadhim Aljarah and Yichun Zheng and Alexander S. Baras and Hiroshi Miyamoto},
  title = {{Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.}},
  booktitle = {PubMed},
  year = {2015},
}
Figure